Titan Pharmaceuticals (TTNP) Shares Gap Down to $0.29

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) gapped down prior to trading on Thursday . The stock had previously closed at $0.31, but opened at $0.29. Titan Pharmaceuticals shares last traded at $0.25, with a volume of 4923151 shares changing hands.

The company has a market cap of $22.89 million, a P/E ratio of -0.41 and a beta of -0.09. The company has a debt-to-equity ratio of 0.76, a current ratio of 5.24 and a quick ratio of 4.65.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings results on Wednesday, November 14th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.03. The business had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $0.10 million. Titan Pharmaceuticals had a negative return on equity of 878.37% and a negative net margin of 168.73%. Equities analysts anticipate that Titan Pharmaceuticals, Inc. will post -0.33 earnings per share for the current year.



In related news, Director James R. Mcnab bought 200,000 shares of Titan Pharmaceuticals stock in a transaction that occurred on Friday, September 21st. The stock was purchased at an average cost of $0.25 per share, for a total transaction of $50,000.00. Following the acquisition, the director now owns 300,000 shares in the company, valued at $75,000. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Marc Rubin bought 400,000 shares of Titan Pharmaceuticals stock in a transaction that occurred on Friday, September 21st. The stock was bought at an average price of $0.25 per share, with a total value of $100,000.00. Following the completion of the acquisition, the chairman now owns 556,317 shares in the company, valued at approximately $139,079.25. The disclosure for this purchase can be found here. In the last three months, insiders purchased 900,000 shares of company stock valued at $225,000. 19.50% of the stock is currently owned by company insiders.

A hedge fund recently bought a new stake in Titan Pharmaceuticals stock. Perkins Capital Management Inc. bought a new position in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,200,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $249,000. Perkins Capital Management Inc. owned about 5.66% of Titan Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 5.66% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Titan Pharmaceuticals (TTNP) Shares Gap Down to $0.29” was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://dakotafinancialnews.com/2018/12/07/titan-pharmaceuticals-ttnp-shares-gap-down-to-0-29.html.

About Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

Recommended Story: 52-Week High/Low

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply